Agenix cuts COO position
Thursday, 27 October, 2005
Brad Calvin is to step down as chief operating officer of Agenix (ASX:AGX) today after the company decided not to renew his employment contract.
Agenix managing director Donald Home will take on Calvin's responsibilities.
The company said Calvin was initially employed to lead the sales and marketing of the Agenix's Animal Health, Human Health and Milton Pharmaceuticals businesses and to assist in the commercialisation of the company's ThromboView product.
Agenix has since divested Milton Pharmaceuticals and entered into an agreement for the global sales, marketing and distribution of ThromboView and the company decided that its requirements for the Animal and Human Health businesses "did not warrant the current level of staffing".
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
Maternal cannabis use puts kids at risk of behavioural problems
Children exposed to their mother's cannabis use during pregnancy and after birth are three...
